Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from postmarketing surveillance

HIGHLIGHTS

• who: Gang Wang and colleagues from the A, week, prospective, multi-center, open-label, postmarketing surveillance was conductedPatients with schizophrenia were recruited from September , to May , from , clinical sites across China. All patients taking blonanserin during the period were included and then followed up. Enrolled patients should orally receive, mg/day of blonanserin according to its approved dose and administration. The dose could be adjusted according to the treatment response and tolerability. The maximum daily dose is , mg. Female patients aged, years were included in this analysis. Efficacy and safety analyses were performed based on the full . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.